Author

Amanda Novak

University of Colorado AnschutzPrimary ORCID profile (0000-0002-9549-7659 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Amanda NovakiD1 paper · Roslin Institute

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Christine R. Brzezinski· 1 shared Dimiter Dmitrov· 1 shared Kole DeGolieriD· 1 shared Lillie Leach· 1 shared Mark Eric KohleriD· 1 shared Terry J. FryiD· 1 shared Zachary H. WalshiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Christine R. Brzezinski

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Rational redesign of antigen binding domain improves in vivo efficacy of CD22-CAR T cells

Kole DeGolier, Zachary H. Walsh, Lillie Leach, Christine R. Brzezinski, Amanda Novak, Dimiter Dmitrov, Mark Eric Kohler, Terry J. Fry

This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.

bioRxiv · Mar 13, 2025 · PreprintImmunology